Department of Geriatrics, The Second Affiliated Hospital of Harbin Medical University, Harbin Heilongjiang 150081, P.R. China.
Can J Physiol Pharmacol. 2010 Jul;88(7):716-23. doi: 10.1139/y10-058.
Peroxisome proliferator-activated receptor gamma (PPARgamma) has been shown to protect against stroke and improve neurological outcome after cerebral ischemia. This study investigated whether activation of cerebral PPARgamma improves recovery from focal cerebral ischemia by reducing expression of cyclin D1, which is associated with programmed neuron death. Focal cerebral ischemia was induced by 90 min of middle cerebral artery occlusion (MCAO), followed by reperfusion. Intracerebroventricular (i.c.v.) infusion of the PPARgamma agonist ciglitazone, beginning 5 days before and continuing through 1 day after MCAO, reduced infarct size and cyclin D1 expression in the peri-infarct cortical region. Furthermore, primary cortical neurons treated with ciglitazone showed suppressed expression of cyclin D1 in response to hypoxia-reoxygenation. This protective effect was reversed after cotreatment with the selective PPAR-gamma antagonist GW 9662 (2-chloro-5-nitrobenzanilide), clearly demonstrating the involvement of a PPARgamma-dependent mechanism. Our data provide evidence that activation of neuronal PPARgamma makes a substantial contribution to neuroprotection by preventing cyclin D1 up-regulation in vitro and in vivo.
过氧化物酶体增殖物激活受体 γ(PPARγ)已被证明可预防中风,并改善脑缺血后的神经功能预后。本研究旨在探讨脑内 PPARγ 的激活是否通过降低与程序性神经元死亡相关的细胞周期蛋白 D1 的表达,从而改善局灶性脑缺血后的恢复。通过 90 分钟的大脑中动脉闭塞(MCAO)诱导局灶性脑缺血,随后再灌注。在 MCAO 前 5 天开始并持续至 MCAO 后 1 天,通过脑室内(i.c.v.)输注 PPARγ 激动剂吡格列酮,可减少梗塞面积和梗塞周边皮质区的细胞周期蛋白 D1 表达。此外,吡格列酮处理的原代皮质神经元在缺氧-复氧时表现出细胞周期蛋白 D1 的表达受到抑制。这种保护作用在与选择性 PPAR-γ 拮抗剂 GW 9662(2-氯-5-硝基苯甲酰胺)共同处理后被逆转,这清楚地表明涉及一种 PPARγ 依赖性机制。我们的数据提供了证据,表明神经元 PPARγ 的激活通过防止体外和体内细胞周期蛋白 D1 的上调,对神经保护做出了实质性的贡献。